| Name | Title | Contact Details |
|---|
ALB is a leading and innovative cloud and web-based platform built by industry experts and lawyers for assisting law firms across the world. ALB is an all-inclusive platform with an easy-to-use dashboard that helps the law firms timekeepers to easily capture details of their daily activities using our mobile or web app. ALB also helps the law firms billing clerk or department to easily prepare and submit accurate invoices to their clients. What makes ALB stand out from any other legal billing software is ALBs skill in being intuitive and to make corrections on line items based on a firms client SLA such that the law firms suffer zero to minimal losses on their invoice amount. Owing to ALBs latest technology, law firms can now prepare and submit invoices to clients that are 100% compliant with their clients SLA. This then results in the firms invoices being processed much faster by a legal bill review vendor or the clients in-house team. Hence the payments are processed much quicker ensuring better cashflow for the firms. Long gone are the days when legal bill vendors cause reductions to the law firms bills.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
ZAETHER is a digital life science consultant and outcome provider for life science leaders seeking proven solutions to known challenges in getting their life science products to market.
The Louis D. Brandeis Center, Inc. (LDB) is an independent, non-partisan institution for public interest advocacy, research and education. The Centers mission is to advance the civil and human rights of the Jewish people and to promote justice for all.